Skip to content
Screener

Bioventus BVS Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue$157.9MBeat by $3.0M
EPS$0.24Beat by $0.02
Revenue estimate$154.9M
EPS estimate$0.22

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$149.5M
EPS estimate$0.17

Financials

Q4 2025

Income statement

See full
Revenue$157.9M+2.8%
Gross profit$108.8M+6.0%
Operating income$19.5M—
Net income$14.8M+3,903%
EPS (diluted)$0.21—

Balance sheet

See full
Cash & equivalents$51.2M+23.2%
Total debt$311.3M-12.6%
Total equity$184.1M+24.4%
Total assets$683.6M-6.1%

Cash flow

See full
Operating cash flow$38.0M+96.5%
CapEx$580.0K+1.0%
Free cash flow$37.4M+99.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$498.3M-27.4%
Enterprise value$758.41M-24.2%
P/E21.9×—
P/S0.9×-0.3×

Profitability

See full
Gross margin68.3%+0.6pp
Operating margin9.5%—
Net margin4%+2.5pp
FCF margin12.7%+6.1pp

Returns & leverage

See full
Return on equity13.7%+8.4pp
Debt / equity1.7×-0.7×
Current ratio1.7×+0.4×

Segments

By segment

See full
U.S. Segment$139.5M+3.2%
International Segment$18.4M-0.1%

FAQ

When did Bioventus report Q4 2025 earnings?
Bioventus (BVS) reported Q4 2025 earnings on March 5, 2026 before market open.
What were Bioventus's Q4 2025 revenue and EPS?
Bioventus reported revenue of $157.9M and eps of $0.24 for Q4 2025.
Did Bioventus beat estimates in Q4 2025?
Revenue beat the consensus estimate of $154.9M by $3.0M. EPS beat the consensus estimate of $0.22 by $0.02.
How did Bioventus's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.8% from $153.6M a year earlier and eps grew 60.0% from $0.15.
Where can I find Bioventus's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001665988-26-000010) and the 10-K periodic report (0001665988-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.